




The relative strengths and weaknesses of Karyopharm Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Karyopharm Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 159% points. The greatest weakness of Karyopharm Therapeutics Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 383%, being 129% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	207,751
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,301
Liabilities, Non-Current	0
Other Assets	9,832
Other Compr. Net Income	40
Other Expenses	0
Other Liabilities	1,242
Other Net Income	0
Other Revenues	229
Property and Equipment	2,754
Research and Development	60,127
Selling, General and Administrative Expense	15,948

Output Variable	Value in 1000 USD
Assets	220,337
Liabilities	13,543
Expenses	76,075
Revenues	229
Stockholders Equity	206,794
Net Income	-75,846
Comprehensive Net Income	-75,826
BaseVar	155,112
ECR before Limited Liability	321%
Economic Capital Ratio	383%